Carcinoma, Bronchogenic  >>  sagopilone (BAY86-5302)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sagopilone (BAY86-5302) / Bayer
NCT00299390 / 2005-000597-53: Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer

Terminated
2
10
Europe
Sagopilone (BAY86-5302, ZK 219477)
Bayer
Small Cell Lung Carcinoma
04/07
04/07
NCT00160069 / 2005-000586-19: Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer

Checkmark Second-line therapy in patients with stage IIIB or IV NSCLC
Mar 2013 - Mar 2013: Second-line therapy in patients with stage IIIB or IV NSCLC
Completed
2
128
Europe
Sagopilone (BAY86-5302, ZK 219477)
Bayer
Carcinoma, Non Small Cell Lung
04/08
04/09
NCT00359359 / 2006-000067-29: A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer

Completed
1/2
26
Europe
Sagopilone (BAY86-5302, ZK 219477), Cisplatin
Bayer
Carcinoma, Small Cell
03/09
08/09

Download Options